Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 6/20 | 0.45 |
| ▸ | CCR5 | P51681 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL428200 | 0.92 | FAAH (0.46) | FAAHCES2MCHR1CCR5GRIN1 | |
| SCHEMBL426170 | 0.90 | FAAH (0.48) | FAAHCES2MCHR1CCR5GRIN1 | |
| SCHEMBL7892004 | 0.88 | FAAH (0.54) | FAAHCES2MCHR1CCR5 | |
| SCHEMBL427987 | 0.87 | FAAH (0.42) | FAAHCES2MCHR1CCR5GRIN1 | |
| SCHEMBL426233 | 0.86 | FAAH (0.45) | FAAHCES2MCHR1CCR5GRIN1 | |
| SCHEMBL427261 | 0.85 | CHRM2 (0.53) | FAAHCES2MCHR1BCHEACHE | |
| SCHEMBL425965 | 0.85 | FAAH (0.61) | FAAHCES2MCHR1GRIN1GRIN2B | |
| SCHEMBL426222 | 0.85 | MCHR1 (0.49) | FAAHCES2MCHR1TP53KMT2A | |
| SCHEMBL425992 | 0.84 | FAAH (0.62) | FAAHCES2MCHR1GRIN1GRIN2B | |
| SCHEMBL16439285 | 0.84 | MCHR1 (0.48) | FAAHCES2MCHR1TP53GRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-9353082-B2 | Pharmaceutical compounds | BIAL—PORTELA & CA, S.A. (PT) | 2016-05-31 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | BIAL - PORTELA & Cª, S.A. (PT) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065191-A1 | PHARMACEUTICAL COMPOUNDS | FAAH, FAAH2, ASAH1 | FAAH 1/4885CES2 62/4885MCHR1 2099/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.